Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
HALONATE
(halobetasol propionate) Ointment, 0.05%
For Dermatological Use Only. Not for Ophthalmic Use.
Halonate Halobetasol Propionate Ointment, 0.05% contains halobetasol propionate, a synthetic corticosteroid for topical dermatological use. The corticosteroids constitute a class of primarily synthetic steroids used topically as an anti-inflammatory and anti-pruritic agent.
Chemically halobetasol propionate is 21-chloro- 6α, 9-dif luoro-11β,17-dihyd roxy-16β- methylpregna-1,4-diene-3-20-dione, 17-propionate, C25H31CIF2O5. It has the following structural formula:
 |
Halobetasol propionate has the molecular weight of 485 It is a white crystalline powder insoluble in water
Each gram of Halobetasol Propionate Ointment contains 0 5 mg/g of halobetasol propionate in a base of aluminum stearate. beeswax, pentaerythritol cocoate. petrolatum, propylene glycol, sorbitan sesquioleate. and stearyl citrate
Halobetasol Propionate Ointment 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis Use in children under 12 years of age is not recommended.
As with other highly active corticosteroids, therapy should be discontinued when control has been achieved If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary
Apply a thin layer of Halobetasol Propionate Ointment to the affected skin once or twice daily, as directed by your physician, and rub in gently and completely.
Halobetasol Propionate Ointment is a super-high potency topical corticosteroid; therefore, treatment should be limited to two weeks, and amounts greater than 50 g/wk should not be used. As with other corticosteroids, therapy should be discontinued when control is achieved If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary Halobetasol Propionate Ointment should not be used with occlusive dressings
Halonate™ is supplied in the following:
(NDC 68712-034-01) one 50 g tube of halobetasol propionate ointment 0.05% packaged with one 4 oz can of ammonium lactate mousse 12%
Store between 15°C and 30°C (59°F and 86°F).
Manufactured by: G&W Laboratories, Inc. South Plainfield, NJ 07080. Manufactured for: JSJ Pharmaceuticals, Charleston, SC 29401. 1 -800-499-4468. www.jsjpharm.com. Issued 05/09
In controlled clinical trials, the most frequent adverse events reported for Halobetasol Propionate Ointment included stinging or burning in 1.6% of the patients Less frequently reported adverse reactions were postulation, erythema, skin atrophy, leukoderma, acne, itching, secondary infection, telangiectasia, urticaria, dry skin, miliaria, paresthesia, and rash.
The following additional local adverse reactions are reported infrequently with topical corticosteroids, and they may occur more frequently with high potency corticosteroids, such as Halobetasol Propionate Ointment. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.
No information provided.
No information provided.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for gluco-corticosleroid insufficiency after withdrawal of treatment Manifestations of Cushing's syndrome hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free-cortisol tests. Patients receiving super potent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression.
Halobetasol Propionate Ointment produced HPA axis suppression when used in divided doses at 7 grams per day for one week in patients with psoriasis These effects were reversible upon discontinuation of treatment
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids For information on systemic supplementation, see prescribing information for those products
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to then larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use).
If irritation develops. Halobetasol Propionate Ointment should be discontinued and appropriate therapy instituted Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
If concomitant skin infections are present or dove lop, an appropriate antifungal or anti-bacterial agent should be used. If a favorable response does not occur promptly, use of Halobetasol Propionate Ointment should be discontinued until the infection has been adequately controlled.
Halobetasol Propionate Ointment should not be used in the treatment of rosacea or perioral dermatitis, and it should not be used on the face, groin or in the axillae.
The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH-stimulation test; A.M. plasma cortisol test; Urinary free-cortisol test.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of halobetasol propionate
Positive mutagenicity effects were observed in two genotoxicity assays Halobetasol propionate was positive in a Chinese hamster micronucleus test, and in a mouse lymphoma gene mutation assay in vitro .
Studies in the rat following oral administration at dose levels up to 50μg/kg/day indicated no impairment of fertility or general reproductive performance.
In other genotoxicity testing, halobetasol propionate was not found to be genotoxic in the Ames/Salmonella assay, in the sister chromatid exchange test in somatic cells of the Chinese hamster, in chromosome aberration studies of germinal and somatic cells of rodents, and in a mammalian spot test to determine point mutations.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic alter dermal application in laboratory animals.
Halobetasol propionate has been shown to be teratogenic in SPF rats and chinchilla-type rabbits when given systemically during gestation at doses of 0.04 to 0.1 mg/kg in rats and 0.01 mg/kg in rabbits. These doses are approximately 13, 33 and 3 times, respectively, the human topical dose of Halobetasol Propionate Ointment. Halobetasol propionate was embryotoxic in rabbits but not in rats.
Cleft palate was observed in both rats and rabbits. Omphalocele was seen in rats, but not in rabbits.
There are no adequate and well-controlled studies of the teratogenic potential of halobetasol propionate in pregnant women. Halobetasol Propionate Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Halobetasol Propionate Ointment is administered to a nursing woman.
Safety and effectiveness of Halobetasol Propionate Ointment in pediatric patients have not been established and use in pediatric patients under 12 is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression. Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation Manifestations of intracranial hypertension include bulging font-anelles, headaches, and bilateral papilledema.
Of approximately 850 patients treated with Halobetasol Propionate Ointment in clinical studies, 21 % were 61 years and over and 6% were 71 years and over. No overall differences in safety or effectiveness were observed between these patients and younger patients; and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Topically applied Halobetasol Propionate Ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Halobetasol Propionate Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Like other topical corticosteroids, halobetasol propionate has anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of the anti- inflammatory activity of the topical corticosteroids, in general, is unclear However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocorins It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid Arachidonic acid is released from membrane phospholipids by phospholipase A2.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier Occlusive dressings with hydrocortisone for up to 24 hours have not bean demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Human and animal studies indicate that less than 6% of the applied dose of halobetasol propionate enters the circulation within 96 hours following topical administration of the ointment.
Studies performed with Halobetasol Propionate Ointment indicate that it is in the super-high range of potency as compared with other topical corticosteroids.
Patients using topical corticosteroids should receive the following information and instructions:
Recommended Use: Maintain mousse can in an upright position when dispensing. Apply by gently massaging a thin layer of Pro:12 Mousse to affected skin areas such as elbows, knees and cracked heels. For best results, use twice a day; ideally one application after showering or bathing to retain moisture. People with fair skin may experience irritation or sensitivity to alpha hydroxyl acid products. If irritation or sensitivity does occur, discontinue use and consult your medical professional for advice.
Firmly push back nozzle until seal is broken. Maintain mousse can in an upright position when pressing the nozzle to dispense.
 |
Do not turn can upside down.
 |
Principal Component: Ammonium lactate 12% (lactic acid neutralized with ammonium hydroxide).
Other ingredients: butane, butylene glycol, butyrospermum parkii. cetyl alcohol, disodium lauriminodipropionate tocopheryl phosphates, helianthus annuus seed oil, hyroxyethyl cellulose, hydroxyphenyl propamidobenzoic acid, laureth-4, pentylene glycol, polysorbate 20, propane, sodium acetate, stearic acid, triethanolamine, water.
Warning: For external use only. Avoid contact with eyes, lips or mucous membranes. Contents under pressure. Do not puncture or incinerate. Keep out of reach of children. Do not store at temperatures above 120°F.
Store at controlled room temperature 15-30° C (59-86°F). Protect from freezing.
For more information or to order Pro:12 Mousse, please visit our website at www.Pro1 2Mousse.com
Or contact us directly to speak with a staff aesthetician at 1-800-499-4468
